Trial Profile
An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome (CAPSS-286) .
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2017
Price :
$35
*
At a glance
- Drugs Topiramate (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Therapeutic Use
- 12 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 May 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 01 Sep 2006 New trial record.